← Back to home

Teva Lifts Its 2026 Revenue Forecast on Strong Austedo and Ajovy Sales

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Teva Pharmaceutical reported third-quarter revenue of $4.395 billion on Tuesday, Nov. 3, down 2% from a…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home